Kazia Therapeutics Ltd

Dec 09, 2020

Top-line Final Data from Cantrixil Phase I Study Confirms Prior Positive Efficacy and Safety Signals

Nov 17, 2020

Kazia Presents Further Paxalisib Data At Sno, Confirming Earlier Positive Safety And Efficacy Signals In Glioblastoma

Oct 16, 2020

Kazia Executes Agreement To Commence GBM Agile Pivotal Study

Aug 23, 2020

US FDA Awards Orphan Drug Designation (ODD) To Paxalisib For Malignant Glioma, Including DIPG

Aug 20, 2020

US FDA Awards Fast Track Designation (FTD) to Paxalisib for Glioblastoma

Aug 07, 2020

US FDA Grants Rare Pediatric Disease Designation (RPDD) to Paxalisib for DIPG

Jun 22, 2020

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs